Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan
Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan
據週四報道，Calliditas Therapeutics和Viatris已在日本啓動Nefecon用於IgA腎病的三期臨床試驗。
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.
臨床試驗是一個橋接研究，需要少數日本患者參與與全球NefIgArd試驗類似設計的研究。IgA腎病是日本指定的可回收疾病，估計有33,000名患者在日本患有該疾病，而該國對IgAN患者的治療選擇有限。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。